2025: A Year of Hope and Progress in the Fight Against Pancreatic Cancer
A Glimmer of Hope in a Challenging Landscape
In a year marked by both triumphs and trials, the pancreatic cancer community witnessed significant strides forward. Despite the disease's formidable reputation, 2025 brought a renewed sense of purpose and collaboration. While pancreatic cancer remains a formidable adversary, with a five-year survival rate below 20%, the year 2025 showcased a growing momentum across research, clinical innovation, and patient advocacy.
But here's where it gets controversial... The federal government's proposed cuts and funding freezes threatened to derail progress, raising concerns about the future of scientific research. However, the community's collective voice proved powerful, prompting Congress to reaffirm its bipartisan support for cancer research. This victory ensures that promising research can continue uninterrupted, offering a glimmer of hope for patients and researchers alike.
Research Recovery Grants: A Bridge to the Future
Amid these challenges, the introduction of PanCAN Research Recovery Grants provided a much-needed safety net. Designed to protect promising research at risk due to funding interruptions, these grants ensure that scientific momentum isn't lost. By sustaining projects with the highest potential impact, these grants safeguard the progress made this year and position the field for even stronger advances in 2026. This initiative reinforces PanCAN's role as a key funder and advocate for pancreatic cancer research.
Breakthroughs in Science and Research
One of the most significant breakthroughs of 2025 was the progress made in targeting RAS, a mutation present in over 90% of pancreatic cancers. After decades of being considered 'undruggable,' RAS is now within reach. The most advanced clinical trial, RASOLUTE 302, recently completed enrollment, testing an investigational drug, daraxonrasib, that targets RAS in patients with metastatic pancreatic cancer. Results from this phase 3 trial are expected in 2026, and the potential impact of a multi-selective inhibitor targeting RAS mutations is immense.
And this is the part most people miss... The importance of this work is further highlighted by Revolution Medicines' receipt of an FDA Priority Review Voucher for daraxonrasib. This achievement recognizes the urgent need for new treatments for pancreatic cancer, and the potential for RAS-directed therapies to benefit patients is immense.
Personalized, Data-Driven Research: Accelerating Progress
The pace of personalized, data-driven research continued to accelerate in 2025. PanCAN's SPARK health data integration platform is transforming how researchers access and analyze patient data, generating insights faster and more collaboratively. By integrating clinical, genomic, pathology, radiology, and patient-reported data, SPARK is helping uncover patterns that better explain disease progression and treatment response.
A Partnership to Watch: PanCAN and Acurion
One particularly exciting development was PanCAN's partnership with Acurion, Inc. to apply its AI-enhanced platform, OncoGaze, to SPARK's digitized pathology images. By identifying tumor patterns and features using advanced computational models, the collaboration aims to uncover actionable biomarkers such as homologous recombination deficiency (HRD). This could lead to more rapid and cost-effective therapy selection, presenting patients with optimal first-line options.
Early Detection: A Key to Survival
Early detection remains a critical focus, and 2025 saw progress in this area. PanCAN's Early Detection Initiative continued to advance research, exploring the impact of blood sugar changes on pancreatic cancer development and diagnosis. The study also gathered information on whether imaging at the time of new-onset diabetes leads to earlier detection. With the completion of enrollment of over 8,800 participants, the initiative will continue monitoring and analyzing data in the coming years, with updates expected in 2026.
A New Treatment Option for PNETs
This year also brought good news with the FDA approval of a new treatment option for patients with pancreatic neuroendocrine tumors (PNETs). CABOMETYX (cabozantinib), a multi-target tyrosine kinase inhibitor, was approved for patients whose tumors progressed after prior therapy. This approval expands treatment options for all pancreatic cancer patients, including those with PNETs, a rare subtype.
Research Milestones at ASCO 2025
The American Society of Clinical Oncology (ASCO) Annual Meeting served as a major platform for pancreatic cancer research. One notable highlight was the phase 3 trial evaluating Novocure's Tumor Treating Fields (TTFields) for locally advanced pancreatic cancer. Adding TTFields to standard chemotherapy improved overall survival, pain-free survival, and distant progression-free survival. Already approved for glioblastoma and lung cancer, TTFields offer hope as a new therapeutic option, with ongoing research refining its integration into treatment.
Scientific Summit 2025: A Catalyst for Change
PanCAN's annual Scientific Summit brought together leading scientists and rising investigators, fostering an incubator for new ideas. The meeting highlighted cutting-edge discoveries in immunotherapy response patterns, metastasis mechanisms, tumor microenvironment biology, and next-generation early detection tools. The Summit demonstrated the strength of collaboration and the importance of supporting early-career investigators.
Patient-Centric Support: A Priority
Advancements in patient-centered support were also a focus in 2025. PanCAN launched a new partnership with Smart Patients, expanding access to an online community where patients and caregivers can connect and share experiences in real-time. This collaboration empowers patients and caregivers, providing them with the support and information they need throughout their pancreatic cancer journey.
PanCAN Research Grants: Fueling Innovation
Despite federal funding challenges, PanCAN announced new research grants supporting projects across early detection, tumor biology, health equity, and emerging therapeutics. These grants fuel innovative work with the potential to shift paradigms and improve outcomes. The grants are part of PanCAN's initial research investment for the fiscal year, with more funding to be announced.
Looking Ahead: A Future of Hope
Although pancreatic cancer remains a leading cause of cancer-related death, 2025 demonstrated clear progress. Advances in AI-powered diagnostics, precision medicine, early detection research, and scientific funding contributed to a year of momentum and purpose. Each discovery, partnership, and initiative brings us closer to a future where early detection is routine, treatments are more effective, and all patients with pancreatic cancer thrive.
PanCAN remains committed to its advocacy work, protecting and increasing federal funding for pancreatic cancer research. With determination and hope, the field is moving forward, turning science into survival. Together, we unite the pancreatic cancer community, pushing boundaries to create a world where survival is the norm, not the exception.
